Cytokines, pulmonary surfactant and consequences of intrauterine infection

Biology of the Neonate

Volumn 76, Issue SUPPL. 1, 1999, Pages 2-9

  Hallman, Mikko ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Bronchopulmonary dysplasia; Persistent fetal circulation syndrome; Preterm infant; Respiratory distress syndrome

Indexed keywords

ANTIOXIDANT; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; LUNG SURFACTANT; NITRIC OXIDE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D;

CHORIOAMNIONITIS; CONFERENCE PAPER; FETUS; FETUS LUNG MATURATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAUTERINE INFECTION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NONHUMAN; PERSISTENT FETUS CIRCULATION; PREMATURE LABOR; PRIORITY JOURNAL;

ANIMALS; CHORIOAMNIONITIS; CYTOKINES; FEMALE; FETAL DEATH; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 0033048598     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047039     Document Type: Conference Paper

References (52)

1. Enhorning G, Robertson B: Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972;50:58-66.
2. Speer CP, Ruess D, Harms K, Herting E, Gefeller O: Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993;91: 794-799.
3. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC: Multi-centre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome: The Curosurf 4 Trial. Arch Dis Child 1993;69: 276-280.
4. Björklund LJ, Vilstrup CT, Larsson A, Svenningsen NW, Werner O: Changes in lung volume and static expiratory pressure-volume diagram after surfactant rescue treatment on neonates with established respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:918-923.
5. Gomez R, Ghezzi F, Romero R, Munoz H, Tolosa JE, Rojas I: Premature labor and intra-amniotic infection: Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol 1995;22:281-342.
6. Bry K, Hallman M: Transforming growth factor-beta 2 prevents preterm delivery induced by interleukin-1 alpha and tumor necrosis factor-alpha in the rabbit. Am J Obstet Gynecol 1993;168:1318-1322.
7. Romero R, Mazor M, Tartakovsky B: Systemic administration of interleukin-1 induces preterm parturition in mice. Am J Obstet Gynecol 1991;165:969-971.
8. Faron G, Boulvain M, Irion O, Bernard PM, Fraser WD: Prediction of preterm delivery by fetal fibronectin: A meta-analysis. Obstet Gynecol 1998;92:153-158.
9. Bonn D: Keeping the stork at bay until the time is right. Lancet 1998; 351:576.
10. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, Cotch MF, Edelman R, Pastorek JG II, Rao AV for the Vaginal Infections and Prematurity Study Group: Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995;333:1737-1742.
11. Hallman M, Lappalainen U, Bry K: Clearance of intra-amniotic lung surfactant: Uptake and utilization by the fetal rabbit lung. Am J Physiol 1997;273:L55-L63.
12. Watterberg KL, Demers LM, Scott SM, Murphy S: Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97:210-215.
13. Hitti J, Krohn MA, Patton DL, Tarczy-Hornoch P, Hillier SL, Cassen EM, Eschenbach DA: Amniotic fluid tumor necrosis factor-alpha and the risk of respiratory distress syndrome among preterm infants. Am J Obstet Gynecol 1997;177:50-56.
14. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI: Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997;177: 825-830.
15. Dammann O, Leviton A: Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997;42:1-8.
16. Zupan V, Gonzalez P, Lacaze-Masmonteil T, Boithias C, d'Allest AM, Dehan M, Gabilan JC: Periventricular leukomalacia: Risk factors revisited. Dev Med Child Neurol 1996; 38:1061-1067.
17. Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM: Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995;346:1449-1454.
18. Bry K, Hallman M, Teramo K, Waffarn F, Lappalainen U: Granulocyte-macrophage colony-stimulating factor in amniotic fluid and in airway specimens of newborn infants. Pediatr Res 1997;41:105-109.
19. Hallman M, Bry K: Interleukin-1 beta and interleukin-1 receptor antagonist in airway specimens of infants with RDS (abstract). Pediatr Res 1993;33:327.
20. Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer CP: Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 1994;93:712-718.
21. Speer C, Groneck B: Oxygen radicals, cytokines, adhesion molecules and lung injury in neonates. Semin Neonatol 1998;3:219-228.
22. Pitkänen OM, Hallman M, Andersson SM: Correlation of free oxygen radical-induced lipid peroxidation with outcome in very low birth weight infants. J Pediatr 1990;116: 760-764.
23. Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Strayer D, Edwards DK III, Gluck L: Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome: Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 1983;72: 656-666.
24. Pitkänen O, Hallman M: Evidence for increased oxidative stress in preterm infants eventually developing chronic lung disease. Semin Neonatol 1998;3:199-205.
25. Jones CA, Cayabyab RG, Kwong KY, Stotts C, Wong B, Hamdan H, Minoe P, de Lemos RA: Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: A possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res 1996;39:966-975.
26. D'Ambola JB, Sherman MP, Tashkin DP, Gong H Jr: Human and rabbit newborn lung macrophages have reduced anti-Candida activity. Pediatr Res 1988;24:285-290.
27. Hallman M, Merritt TA, Akino T, Bry K: Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid: Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am Rev Respir Dis 1991;144:1376-1384.
28. Hallman M, Merritt TA, Bry K: The fate of exogenous surfactant in neonates with respiratory distress syndrome. Clin Pharmacokinet 1994; 26:215-232.
29. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR: Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 1997;158:4336-4340.
30. Botas C, Poulain F, Akiyama J, Brown C, Allen L, Goerke J, Clements J, Carlson E, Gillespie AM, Epstein C, Hawgood S: Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc Natl Acad Sci USA 1998;95:11869-11874.
31. Wright JR: Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-962.
32. Goetzman BW, Read LC, Plopper CG, Tarantal AF, George-Nascimento C, Merritt TA, Whitsett JA, Styne D: Prenatal exposure to epidermal growth factor attenuates respiratory distress syndrome in rhesus infants. Pediatr Res 1994;35: 30-36.
33. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, et al: Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995; 269:230-234.
34. Uy C, Bry K, Ibardolaza M, Lappalainen U, Hallman M: Granulocyte-macrophage colony-stimulating factor (GM-CSF) increases the surfactant phospholipid in the premature rabbit (abstract). Pediatr Res 1997; 41:151.
35. Ikegami M, Ueda T, Hull W, Whitsett JA, Mulligan RC, Dranoff G, Jobe AH: Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am J Physiol 1996; 270:L650-L658.
36. Bry K, Hallman M: Amniotic fluid administration of interleukin-1 alpha (IL-1a) or interleukin-1 receptor antagonist (IL-1ra): Effects on surfactant protein expression (abstract). Am J Respir Crit Care Med 1995;151:23.
37. Bry K, Lappalainen U, Hallman M: Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J Clin Invest 1997;99:2992-2999.
38. Emerson GA, Bry K, Hallman M, Jobe AH, Wada N, Ervin MG, Ikegami M: Intra-amniotic interleukin-1 alpha treatment alters postnatal adaptation in premature lambs. Biol Neonate 1997;72:370-379.
39. Bry K, Lappalainen U, Hallman M: Maturational effects of IL-1 on fetal lungs are dependent on route of cytokine administration (abstract). Pediatr Res 1997;41:42.
40. van Helden H, Kuijpers W, Steenvoorden D, Go C, Bruijnzeel PL, van Eijk M, Haagsman HP: Intratracheal aerolization of endotoxin (LPS) in the rat: A comprehensive animal model to study adult (acute) respiratory distress syndrome. Exp Lung Res 1997;23:297-316.
41. Bachurski CJ, Pryhuber GS, Glasser SW, Kelly SE, Whitsett JA: Tumor necrosis factor-alpha inhibits surfactant protein C gene transcription. J Biol Chem 1995;270:19402-19407.
42. Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, Piguet PF, Vassalli P: Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96: 250-259.
43. Whitsett JA, Weaver TE, Lieberman MA, Clark JC, Daugherty C: Differential effects of epidermal growth factor and transforming growth factor-beta on synthesis of Mr = 35,000 surfactant-associated protein in fetal lung. J Biol Chem 1987;262:7908-7913.
44. Ballard PL, Liley HG, Gonzales LW, Odom MW, Ammann AJ, Benson B, White RT, Williams MC: Interferon-gamma and synthesis of surfactant components by cultured human fetal lung. Am J Respir Cell Mol Biol 1990;2:137-143.
45. Glumoff V, Väyrynen O, Kangas T, Hallman M: Effects of IL-1 on the expression of surfactant proteins are dependent on degree of maturity (abstract). Pediatr Res 1998;44:456.
46. Nelson KB, Dambrosia JM, Grether JK, Phillips TM: Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:665-675.
47. Merritt TA, Hallman M, Holcomb K, Strayer D, Bloom B, Revak S, Cochrane CG: Human surfactant treatment of severe respiratory distress syndrome: Pulmonary effluent indicators of lung inflammation. J Pediatr 1986;108:741-748.
48. Meadow W, Rudinsky B: Inflammatory mediators and neonatal sepsis: Rarely has so little been known by so many about so much. Clin Perinatol 1995;22:519-536.
49. Hallman M, Merritt TA, Bry K, Berry C: Association between neonatal care practices and efficacy of exogenous human surfactant: Results of a bicenter randomized trial. Pediatrics 1993;91:552-560.
50. Pelkonen AS, Hakulinen AL, Turpeinen M, Hallman M: Effect of neonatal surfactant therapy on lung function at school age in children born very preterm. Pediatr Pulmonol 1998;25:182-190.
51. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrøm K, Jacobsen T for the Danish-Swedish Multicenter Study Group: Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994;331: 1051-1055.
52. Anttila E, Pokela M-L, Hallman M: Prospective paired comparison of short early vs. late dexamethasone (DX) treatment of small premature infants. Pediatr Res 1998;44:439.